August 2010
Myomics and Novartis Pharma expand their drug screening service agreement.
July 2010
Myomics files a new patent application ofr repurposing a class of FDA-approved drugs for skeletal muscle disorders.
February 2010
Myomics expands into new state-of-the-art laboratory space at West River Center, Providence, RI.
January 2010
Massachusetts General Hospital publishes a news article about Dr. Brian Tseng's research partnership with Dr. Vandenburgh and Myomics to find optimal treatments for Duchenne Muscular Dystrophy. "Cutting Edge Research...."
November 2009
Patent application filed jointly by Massachusetts General Hospital and Myomics, Inc., with regard to new treatment for Duchenne Muscular Dystrophy patients.
November 2009
Myomics receives 2009 Best of Business Award in the Biotechnical research, commercial category from the Small Business Commerce Association. Press Release.
September 2009
Myomics muscular dystrophy article published in FASEB Journal :: mORE
May 2009
SVM publishes an article about Myomics, as a follow-up to Boston Globe. " Tiny New England Biotech Leading the Way in Fight against Muscular Dystrophy"
May 2009
Boston Globe publishes an article about Myomics - Massachusetts General Hospital -Jett Foundation research collaboration regarding Duchenne Muscular Dystrophy. "Strength in Numbers"
February 2009
Myomics
MFAS™
assay validated by the Center for Genetic Medicine Research, Children’s National Medical Center, Washington, DC.
December 2008
Myomics signs compound screening agreement with Novartis Pharma AG.
July 2008
Myomics'
MFAS™
assay validated by Novartis Pharma AG.
May 2008
Myomics signs compound screening agreement with Jett Foundation.
September 2007
Cell Cure, Inc. merges with Myomics, Inc.
